Last reviewed · How we verify
NCT03535441
HMGB1 Release From Hemorrhagic Shock Patients
trial in Intensive Care Unit in 18 participants. Completed in 11 May 2018.
11 April 2018
Quick facts
| Lead sponsor | Xingui Dai |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 18 |
| Start date | 17 May 2017 |
| Primary completion | 11 April 2018 |
| Estimated completion | 11 May 2018 |
| Sites | 1 location across China |
Conditions studied
- Intensive Care Unit — all drugs for Intensive Care Unit →
- Hemorrhagic Shock — all drugs for Hemorrhagic Shock →
- Adult Disease — all drugs for Adult Disease →
Sponsor
Xingui Dai
Who can join
18 and older, any sex, with Intensive Care Unit or Hemorrhagic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is reported that high mobility group box 1 (HMGB1), a non-histone nuclear protein, can serve as an alarmin with damage associated molecular patterns to activate immune responses in the early stages of hemorrhagic shock (HS). However, the origin of HMGB1 and how it is released following HS is poorly understood. In this study, we teased out this mechanism. We try to record the concentration of serum HMGB1 protein following HS in clinical patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.
Birmpilis AI, Paschalis A, Mourkakis A, Christodoulou P, et al · · 2022 · cited 66× · PMID 35563721 · DOI 10.3390/cells11091415
Verify or expand the search:
- PubMed search for NCT03535441
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intensive Care Unit
Currently open trials in the same condition.
- NCT05451875 — Validation of Vital Signs Recording With VT-Patch Connected Devices in Children · recruiting
- NCT06556914 — Effect of Albumin Replacement on Oxygen Delivery in Sepsis Patients · recruiting
- NCT07200817 — Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Ou · recruiting
- NCT06481644 — Asia Pediatric Intensive Care Epidemiology and Outcomes Study · recruiting
- NCT06466811 — Prediction of Undesired Obstruction in External Ventricular Drains. · recruiting
Other Xingui Dai trials
Trials by the same sponsor.
- NCT07198490 — Construction of a Prognostic Model for Severe Brain-Injured Patients Based on Integrated Metabolic-Neurological Monitori · not yet recruiting
- NCT06336265 — Diaphragmatic Ultrasound to Predict the Therapeutic Effect of High-flow Nasal Cannula Oxygen Therapy · unknown
- NCT03420560 — A Warmer Temperature Decrease Propofol Injection Pain · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03535441 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xingui Dai
- Last refreshed: 24 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03535441.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing